SUMMARY Production of interferon alfa in vitro was significantly reduced during acute respiratory syncytial virus bronchiolitis but subsequently returned to normal. Nasopharyngeal and endotracheal interferon alfa were detected intermittently and in low concentrations. The degree of impairment of in vitro production and poor in vivo production of interferon alfa suggest the need for a therapeutic trial of nebulised or systemic interferon in acute bronchiolitis.
Infection by respiratory syncytial virus is one of the main causes of infant morbidity and mortality throughout the world causing annual winter epidemics of bronchiolitis with or without pneumonia, yet comparatively little is known about the mechanisms of resistance to-and recovery frominfection.' Maternal antibody does not completely protect against infection and some of the most severe infections occur in infants with the highest titres of passive antibody. Pre-existing secretory antibody in adults correlates with protection2 but there is no good evidence of similar protection in infants,3 although the appearance of secretory IgA correlates with falling titres of virus in infected infants.4
Local production of interferon is an important defence mechanism in many respiratory virus infections, and may limit viral replication until other host defence mechanisms (such as local and systemic antibody production) are activated. Little or no nasal interferon is produced in respiratory syncytial virus infection compared with other respiratory virus infections.S 6 Nevertheless, respiratory syncytial virus is acutely sensitive to interferon in vitro7 and evidence of poor interferon production suggests a disease in which the therapeutic use of interferon could be envisaged. The aim of the present study was to examine further the production of interferon in vitro and in vivo in infants with respiratory syncytial virus bronchiolitis.
Patients and methods
The index group comprised 64 infants aged 2 (Wellcome) to stimulate production of interferon gamma. Supernatants were frozen at -70°C until assayed. Nasopharyngeal secretions were obtained from index patients (serially when possible) during the acute phase of the infection by suction using a mucus aspirator and trap (Vygon) at the same time as routine nasal suction was being carried out. Endotracheal secretions were obtained from infants requiring artificial ventilation using the same mucus aspirator and a thin catheter.
Whenever possible serial tenfold dilutions of the nasopharyngeal or endotracheal secretions were made in phosphate buffered saline and 0-2 ml duplicate dilutions inoculated on to monolayers of HEp2 cells. These were grown in roller drums at 33°C for two weeks or until the typical cytopathic effect developed. The titre of respiratory syncytial virus in a specimen was taken as the reciprocal of the highest dilution in which the cytopathic effect was seen. Supernatants from the original secretions, diluted 5-10 times in phosphate buffered saline A, were frozen at -70°C until assayed for interferon.
In vitro mononuclear cell culture supernatants, and supernatants from nasopharyngeal and endotracheal secretions, were assayed for interferon alfa and interferon gamma with separate highly sensitive and specific immunoradiometric assays (Boots Celltech).
Statistical analysis was by Student's t test and x2 testing. Informed parental consent was obtained and the study was approved by the central Oxford research ethics committee.
Results
Peripheral blood mononuclear cell interferon alfa production in vitro was significantly lower in the 64 patients with acute respiratory syncytial virus infections than in the 21 control subjects (geometric mean (1 SD) 26X8 (6-5-109.6) compared with 138-9 (23-6-818.5) IU/ml, p<0-001) (fig 1) . This was not caused by a primary defect in in vitro production of interferon alfa, because production of interferon alfa was normal in 22 of the patients with respiratory syncytial virus when they were convalescent (geometric mean (1 SD) 166-6 (55-6500) IU/ml, p<0-001 compared with the patients with acute infections but not significantly different from the control subjects). There was no correlation between severity of disease and in vitro production of interferon alfa (fig 2) .
There was no difference between in vitro production of interferon gamma by 41 patients during acute respiratory syncytial virus infection (geometric mean (1 SD) 39-3 (8-0-193-1) IU/ml), 14 The results of this study, and those of Hall et a15 and McIntosh,f suggest that it is unlikely that production of interferon alfa is an important in vivo mechanism for preventing or ameliorating respiratory syncytial virus infection. It is not understood why respiratory syncytial virus is such a poor inducer of interferon alfa, but this has now been shown both in vivo and in vitro. 13 We have also shown that there is significant but reversible impairment of the ability of mononuclear cells from infected infants to produce interferon alfa in vitro in response to a standard viral stimulus. Newcastle disease virus, a paramyxovirus, was deliberately chosen because it is similar to respiratory syncytial virus. Although the 
degree of impairment of production of interferon alfa could not be associated with the severity of the disease, it may well be an important sign of the transient suppressive effect of respiratory syncytial virus infection on interferon production.
Natural or recombinant interferon alfa has little or no therapeutic effect on respiratory virus infections when given intranasally or systemically after infection is established.14 This is probably because respiratory viruses are generally potent stimulators of local, nasal, and sometimes serum production of interferon,5 6 which may already be maximal by the time treatment with interferon can be started.
On the other hand, interferon alfa can be given prophylactically to prevent respiratory infections. Two recent studies have shown that an intranasal spray of interferon taken prophylactically by the family contacts of an index case with a cold, protected the contacts against developing colds caused by rhinoviruses, though not against infections due to parainfluenza, influenza, coronaviruses, or Mycoplasma pneumoniae.15 16 If the possible use of interferon against respiratory syncytial virus infection is to be considered there are two likely approaches: to use a nasal spray prophylactically in infants in contact with a cold (contact prophylaxis) or to use interferon to treat infants with established bronchiolitis (therapeutic use). Respiratory syncytial virus infections are generally introduced into the family by a schoolchild'1 so that it is theoretically possible to give an intranasal spray to parents to be given to a baby (perhaps any infants less than 6 months old or those at high risk of severe respiratory syncytial virus infection) when another family member develops a winter respiratory infection (contact prophylaxis). Current intranasal preparations have, however, caused considerable local toxicity in adults leading to nasal irritation, hyperaemia, bleeding, and ulceration'5 16 and it is likely that drops or sprays would be poorly tolerated by babies.
There is good reason to suspect that interferon might be successful in treating respiratory syncytial virus infection, even when infection is established. Local nasal production of interferon alfa is high during most respiratory virus infections but low during respiratory syncytial virus infection.5 6 We have now shown that mononuclear cells from infants with respiratory syncytial virus bronchiolitis produce significantly less interferon alfa than cells from control subjects or cells from infants recovered from respiratory syncytial virus, suggesting a suppressive effect on production of interferon alfa by respiratory syncytial virus. On the other hand, respiratory syncytial virus is extremely sensitive to the action of interferon in vitro. 7 The combination of a virus that does not induce production of interferon but which is highly sensitive to its action-as in respiratory syncytial virus bronchiolitis-would seem ideal for a therapeutic trial of interferon. Because 
